Order Article Reprints

Gautron Moura B, Gerard CL, Testart N, Caikovski M, Wicky A, Aedo-Lopez V, Berthod G, Homicsko K, Prior JO, Dromain C, et al. Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. Cancers. 2023; 15(1):31. https://doi.org/10.3390/cancers15010031

Gautron Moura, Bianca, Camille L. Gerard, Nathalie Testart, Marian Caikovski, Alexandre Wicky, Veronica Aedo-Lopez, Grégoire Berthod, Krisztian Homicsko, John O. Prior, Clarisse Dromain, and et al. 2023. "Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma" Cancers 15, no. 1: 31. https://doi.org/10.3390/cancers15010031

Gautron Moura, B., Gerard, C. L., Testart, N., Caikovski, M., Wicky, A., Aedo-Lopez, V., Berthod, G., Homicsko, K., Prior, J. O., Dromain, C., Kandalaft, L. E., Cuendet, M. A., & Michielin, O. (2023). Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. Cancers, 15(1), 31. https://doi.org/10.3390/cancers15010031